What this is
- This study investigates the effects of empagliflozin on hemodynamic parameters in patients with type 2 diabetes (T2D).
- The focus is on early and delayed changes in cardiac function and filling pressure over a 3-month period.
- Findings indicate empagliflozin does not significantly alter systemic vascular resistance or cardiac index but improves left ventricular filling pressure.
Essence
- Empagliflozin treatment in T2D patients does not affect hemodynamic parameters but significantly improves left ventricular filling pressure shortly after administration.
Key takeaways
- Empagliflozin increased urinary glucose excretion from 7.3 ± 22.7 g/24 h at baseline to 48.4 ± 34.7 g/24 h by day 1 (p < 0.001).
- Left ventricular filling pressure improved significantly, with E/e' decreasing from 9.2 ± 2.6 at baseline to 8.5 ± 2.2 by day 1 (p = 0.005).
- No significant changes were observed in cardiac index, stroke volume index, or systemic vascular resistance index at any time point.
Caveats
- The study's exploratory nature limits the generalizability of findings, requiring confirmation in larger populations.
- Non-invasive hemodynamic measurements may not capture all relevant cardiovascular changes, and other parameters were not assessed.
Simplified
Background
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are glucose-lowering drugs currently used to treat patients with type 2 diabetes mellitus (T2D). These agents act by inhibiting SGLT2 in the proximal tubule of the kidney with a subsequent increase in urinary glucose excretion thus lowering blood glucose levels. Several placebo-controlled cardiovascular outcome trials (CVOTs) with SGLT2 inhibitors (EMPA-REG OUTCOME with empagliflozin [1], the CANVAS program [2] and CREDENCE [3] with canaglifozin, DECLARE with dapagliflozin [4], VERTIS with Ertugliflozin [5]) demonstrated a reduction in CV events as well as a reduction in hospitalisation for heart failure (HHF) in patients with T2D and atherosclerotic CV disease (ASCVD), multiple CV risk factors, or diabetic nephropathy. Moreover, the favourable effects of SGLT2 inhibitors on HHF and CV death in these trials were present in patients with or without HF at baseline [6], suggesting that these agents could prevent the development of HF in patients with T2D. In addition, data from the DAPA-HF [7] and the EMPEROR reduced trial [8] suggest that SGLT2 inhibitors may reduce HF related endpoints and CV death even independent of the presence of diabetes.The underlying mechanisms of these beneficial effects of SGLT2 inhibitors on HF-related events remain unclear but changes in blood pressure, blood glucose, or body weight are unlikely to solely explain the observed results. The early separation of HHF event curves in the CVOTs suggested SGLT2 inhibition to provide immediate effects on volume status and/or modulation of hemodynamic parameters potentially mediated by early diuretic effects [9–13]. Therefore, we conducted a prospective, placebo-controlled, double blind, randomized, exploratory pilot study in patients with T2D to assess the effect of empagliflozin on urinary volume, left ventricular filling pressure and function in addition to hemodynamic parameters after 1 day, 3 days and 3 months of treatment.
Methods
Study population and study design
In this single center, prospective, placebo-controlled, double blind, randomized, 2-arm parallel, interventional and exploratory pilot study 44 patients with T2D were randomized into 2 groups. The randomisation list was computer generated using a permuted block randomisation with block size of 4. The sequence generation method and the block size was concealed from the investigators. An independent pharmacist labelled the study medications according to the randomisation list. Study participants received empagliflozin 10 mg or placebo for a period of 3 months in addition to their concomitant medication. Non-invasive hemodynamic measurement, transthoracic echocardiography, blood pressure, blood- and urine-chemistry were performed at baseline (day 0), day 1, day 3 and after 3 months. Participants were recruited from the Department of Internal Medicine I at University Hospital Aachen, RWTH Aachen University, Germany. Inclusion criteria were as follows: type 2 diabetes, HbA1c ≥ 6.5% and age ≥ 18 years. Exclusion criteria were type 1 diabetes, uncontrolled hypertension, age ≥ 85 years, pregnancy, renal impairment (eGFR < 30 mL/min/1.73 m2), liver disease (serum levels of AST, ALT or AP more than three times the upper limit of normal), uncontrolled thyroid disease, endocrinopathies like Graves’ disease, akromegaly, Cushings’ disease, secondary hypertension due to renal artery stenosis, pheochromocytoma or hyperaldosteronism, hypertensive retinopathy or encephalopathy, acute coronary syndrome, stroke or transient ischemic attack in last 6 weeks prior to randomization. The study protocol was approved by the local ethic committee and all subjects gave written informed consent. The trial was registered: EudraCT Number: 2016-000172-19.
Laboratory measurement
Serum chemistry including haematology, lipid profile, glucose metabolism, eGFR (CKD-EPI formula), cystatin C, NT-proBNP, aldosterone were performed at every visit of the clinical trial. We collected 24 h urine at baseline, day 1, day 3 and after 3 months to measure renal excretion of glucose and sodium.
Hemodynamics
We used ClearSight System® (Edwards Lifesciences, Irvine, USA) as a validated [14] non-invasive tool to explore effects of empagliflozin on hemodynamic parameters including cardiac index (CI), stroke volume index (SVI), heart rate (HR), and systemic vascular resistance index (SVRI) at baseline, day 1, day 3 and after 3 months. ClearSight System® uses finger arterial pressure measurement based on the volume clamp method in combination with Physiocal calibration. Dividing the systolic area of the time integral of the pressure curve above the diastolic pressure by the estimated arterial impedance gives a beat-to-beat stroke volume which is multiplied with the heart rate to reach cardiac output, as has been described previously [14].
Transthoracic echocardiography
Transthoracic and Doppler echocardiography were performed by technicians blinded to clinical information and treatment assignment with commercially available ultrasound systems (GE Healthcare, Chicago, USA). Standardized echocardiographic measurements were obtained in accordance with the guidelines of the EACI (European Association of Cardiovascular Imaging) and ASE (American Society of Echocardiography). Left ventricular systolic function (EF) was measured in 4 chamber and 2 chamber views by Simpson’s Biplane Method. Additionally we performed myocardial deformation analysis of the left ventricle to assess peak global longitudinal strain (GLS) of the endocardial layer by speckle-tracking echocardiography in 4 chamber, 2 chamber and apical 3 chamber views. For diastolic function we determined early (E) and late (A) diastolic mitral inflow velocities, deceleration time (DT), septal early diastolic mitral annular tissue velocity (septal eʹ) and lateral early diastolic mitral annular tissue velocity (lateral eʹ) by mitral pulse wave Doppler and tissue Doppler. We calculated E/e' ratio and E/A ratio by dividing E peak by average eʹ calculated from septal eʹ and lateral eʹ respectively E peak by A. Additionally we performed myocardial deformation imaging as determined by 2D and 3D parameter global strain rate. Images were stored digitally for subsequent offline analysis. Interpretation of the echocardiograms was performed by two independent blinded investigators. Interobserver variability of the key echocardiographic endpoints E and eʹ was 0.8 for E and 0.77 for eʹ.
Endpoints
The study was powered for primary study outcome of empagliflozin on systemic vascular resistance index (SVRI) in comparison to placebo after 1 day, 3 days and 3 months of treatment. Secondary endpoints included changes in the following parameters after 1 day, 3 days and 3 months: cardiac index (CI), stroke volume index (SVI), blood pressure, sodium excretion in 24 h urine collection, body weight, heart rate, serum levels of NT-proBNP, cystatin C, glucose, HbA1c and aldosterone.
Further secondary analysis included changes in left ventricular systolic function as determined by EF and GLS, and in left ventricular diastolic function as determined by standardized parameters.
Statistical analysis
The sample size calculation was conducted based on a repeated measure analysis of variance of the primary endpoint including baseline and 3 repeated measures, 2 treatment levels, and a treatment-by-time interaction tested using an F-Test. A mean difference of zero at baseline and constant differences over time were assumed, and a standard deviation of 930 dynes s cm−5 m−2 was used based on sample standard deviation in previous work [15]. The correlation structure was assumed to follow compound symmetry with correlation of 0.3. A significance level of 5% and a power of 80% were chosen. Based on these assumptions, a total of 42 patients allows a detection of a minimal difference of 800 dynes s cm−5 m−2 in SVRI.
Descriptive statistics of baseline characteristics were calculated as relative (%) and absolute frequencies for categorical variables. Quantitative variables were described as means and standard deviations, in case of non-normally distributed data, as median with 1st and 3rd quartiles. Data distributions were visualized using box-plots.
Outcome variables were analysed using linear mixed models with fixed effects for treatment, visits (day 1, day 3 and 3 months) and baseline measurement of the variable. For the primary endpoint analysis, randomisation blocks were also included as fixed effect. The random part of the models consisted of intercepts grouped by individuals. Restricted maximum likelihood estimation was used. For NT-proBNP the log transformed variable was used in the analyses. Treatment effects were estimated at each visit along with Wald type 95% confidence intervals. For the primary endpoint the null hypothesis that all treatment-visit interactions are zero was tested against the alternative that at least one of them is not zero using an F test. Kenward–Roger approximation of the degrees of freedom was used. As additional analyses, correlation between changes from baseline to 3 months were calculated for selected variables using the Pearson correlation coefficient, and changes from baseline were compared between treatment groups separately at each visit. Results were not adjusted for multiple comparison.
Results
Baseline characteristics
| Placebo (N = 22) | Empagliflozin (N = 20) | p | |
|---|---|---|---|
| Age—years | 61.2 ± 7.9 | 62.8 ± 5.4 | 0.466 |
| Male—no. (%) | 18 (81.8) | 16 (80) | 0.881 |
| BMI—kg/m2 | 31.2 ± 4.0 | 31.4 ± 5.3 | 0.905 |
| Systolic blood pressure—mmHg | 136 ± 18 | 135 ± 16 | 0.934 |
| Diastolic blood pressure—mmHg | 81 ± 14 | 82 ± 13 | 0.964 |
| Heart rate—bpm | 69 ± 15 | 71 ± 12 | 0.587 |
| Type 2 diabetes | |||
| Glycated hemoglobin—% | 7.9 ± 1.3 | 7.5 ± 0.9 | 0.228 |
| Diabetes duration—years | 9 (6–18) | 10 (4–14) | 0.523 |
| Insulin treated—no. (%) | 8 (36) | 11 (55) | 0.475 |
| Metformin—no. (%) | 18 (82) | 13 (65) | 0.41 |
| DPP-4 inhibitors—no. (%) | 6 (27) | 8 (40) | 0.552 |
| Others—no. (%) | 1 (5) | 3 (15) | 0.308 |
| History of CVD—no. (%) | |||
| Coronary heart disease | 15 (68.2) | 15 (75) | 0.625 |
| Myocardial infarction | 10 (45.5) | 5 (25) | 0.205 |
| CABG | 4 (18.2) | 4 (20) | 0.881 |
| PCI | 12 (54.5) | 10 (50) | 0.768 |
| Peripheral artery disease | 2 (9.1) | 4 (20) | 0.313 |
| Chronic heart failure—no. (%) | 11 (50) | 7 (35) | 0.327 |
| Medication—no. (%) | |||
| Antiplatelets | 16 (73) | 11 (55) | 0.975 |
| Oral anticoagulants | 5 (23) | 6 (30) | 0.914 |
| Diuretics | 10 (45) | 10 (50) | 0.549 |
| Statins | 15 (68) | 15 (75) | 0.455 |
| Calcium channel blockers | 5 (23) | 4 (20) | 0.637 |
| Beta blockers | 16 (73) | 16 (80) | 0.345 |
| RAAS inhibitors | 20 (91) | 15 (75) | 0.115 |
| e GFR—mL/min/1.73 m2 | 88 ± 16 | 77 ± 21 | 0.076 |
| Total cholesterol—mg/dL | 155 ± 39 | 169 ± 41 | 0.257 |
| LDL-C—mg/dL | 95 ± 38 | 103 ± 36 | 0.522 |
| HDL-C—mg/dL | 44 ± 9 | 43 ± 9 | 0.53 |
| Triglycerides—mg/dL | 156 ± 71 | 245 ± 150 | 0.023 |
Effect of empaglifozin on hemodynamic parameters
Hemodynamic parameters. Systemic vascular resistance index (SVRI) (), cardiac index (CI) (), stroke volume index (SVI) (), and heart rate (HR) () in patients with type 2 diabetes treated with empagliflozin (n = 20; black line) or placebo (n = 22; blue dotted line). Data are shown as mean ± standard error at baseline, after 1 day, 3 days, and 3 months. p-values are calculated from Wald tests for the intervention effect at each visit a b c d
| Baseline | Day 1 | Day 3 | Month 3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Empagliflozin | p | Placebo | Empagliflozin | p | Placebo | Empagliflozin | p | Placebo | Empagliflozin | p | |
| Laboratory | ||||||||||||
| Glucose—mg/dL | 175 ± 52 | 181 ± 75 | 0.742 | 171 ± 48 | 152 ± 38 | 0.049 | 166 ± 52 | 146 ± 35 | 0.037 | 156 ± 52 | 151 ± 42 | 0.754 |
| HbA1c—% | 7.9 ± 1.3 | 7.5 ± 0.9 | 0.228 | 7.9 ± 1.3 | 7.4 ± 0.9 | 0.722 | 7.9 ± 1.2 | 7.4 ± 0.9 | 0.69 | 7.8 ± 1.5 | 7.1 ± 0.7 | 0.595 |
| Total cholesterol—mg/dL | 155 ± 39 | 169 ± 41 | 0.257 | 155 ± 37 | 174 ± 43 | 0.178 | 152 ± 40 | 168 ± 39 | 0.824 | 152 ± 42 | 185 ± 48 | 0.001 |
| LDL-C—mg/dL | 95 ± 38 | 103 ± 36 | 0.522 | 94 ± 36 | 102 ± 36 | 0.915 | 93 ± 39 | 102 ± 40 | 0.477 | 89 ± 39 | 112 ± 47 | <0.001 |
| HDL-C—mg/dL | 44 ± 9 | 43 ± 9 | 0.53 | 44 ± 9 | 42 ± 10 | 0.947 | 44 ± 9 | 43 ± 9 | 0.9 | 46 ± 11 | 46 ± 10 | 0.937 |
| eGFR—mL/min/1.73 m2 | 88 ± 16 | 77 ± 21 | 0.076 | 85 ± 16 | 70 ± 19 | 0.014 | 85 ± 17 | 70 ± 21 | 0.039 | 85 ± 16 | 68 ± 20 | 0.108 |
| Cystatin C—mg/L | 1.0 ± 0.2 | 1.2 ± 0.4 | 0.148 | 1.0 ± 0.2 | 1.3 ± 0.4 | <0.001 | 1.0 ± 0.2 | 1.3 ± 0.4 | 0.001 | 1.0 ± 0.2 | 1.3 ± 0.4 | <0.001 |
| NT-proBNP—pg/mL | 166 (73–238) | 239 (91–463) | 0.481 | 168 (67–252) | 192 (63–385) | 0.224 | 147 (58–226) | 173 (57–402) | 0.408 | 158 (42–262) | 133 (32–500) | 0.723 |
| Aldosterone—pg/mL | 83 ± 33 | 104 ± 65 | 0.213 | 88 ± 32 | 111 ± 67 | 0.825 | 96 ± 50 | 108 ± 59 | 0.635 | 108 ± 71 | 137 ± 104 | 0.522 |
| 24 h urine | ||||||||||||
| Urinary volume—mL/24 h | 1788 ± 756 | 1740 ± 601 | 0.829 | 1626 ± 681 | 2112 ± 837 | 0.011 | 2007 ± 913 | 2111 ± 758 | 0.429 | 1664 ± 594 | 2319 ± 873 | 0.001 |
| Glucose excretion—g/24 h | 10.9 ± 22.7 | 7.3 ± 22.7 | 0.617 | 6.9 ± 14.1 | 48.4 ± 34.7 | <0.001 | 7.5 ± 14.5 | 65.7 ± 43.3 | <0.001 | 10.2 ± 18.7 | 67.6 ± 50.9 | <0.001 |
| Sodium excretion—mmol/24 h | 196 ± 84 | 164 ± 88 | 0.255 | 181 ± 76 | 185 ± 111 | 0.223 | 203 ± 107 | 181 ± 126 | 0.97 | 175 ± 55 | 201 ± 145 | 0.054 |
| Electrolyte-free water clearance—mL/24 h | − 15 ± 721 | 166 ± 830 | 0.467 | − 124 ± 654 | 417 ± 802 | 0.011 | 90 ± 874 | 461 ± 551 | 0.07 | − 91 ± 597 | 380 ± 765 | 0.013 |
| Body weight—kg | 94.0 ± 14.0 | 95.8 ± 17.3 | 0.724 | 94.1 ± 14.1 | 94.9 ± 17.0 | 0.044 | 94.0 ± 14.1 | 94.5 ± 17.2 | 0.007 | 93.7 ± 14.3 | 96.0 ± 19.6 | 0.059 |
| Hemodynamics | ||||||||||||
| CI—L/min/m2 | 3.2 ± 0.6 | 3.2 ± 0.6 | 0.682 | 3.1 ± 0.5 | 3.1 ± 0.5 | 0.771 | 3.1 ± 0.5 | 3.0 ± 0.6 | 0.293 | 3.1 ± 0.5 | 3.1 ± 0.5 | 0.303 |
| SVI—mL/b/m2 | 50 ± 7 | 47 ± 7 | 0.266 | 48 ± 8 | 45 ± 8 | 0.344 | 48 ± 8 | 44 ± 8 | 0.131 | 47 ± 7 | 47 ± 7 | 0.879 |
| SVRI—dyne*s*cm*m−5−2 | 1836 ± 361 | 1841 ± 379 | 0.967 | 1942 ± 355 | 1864 ± 373 | 0.411 | 1831 ± 310 | 1837 ± 376 | 0.991 | 1909 ± 428 | 1908 ± 451 | 0.795 |
| HR—bpm | 66 ± 13 | 68 ± 12 | 0.665 | 65 ± 11 | 69 ± 13 | 0.122 | 66 ± 11 | 68 ± 14 | 0.717 | 66 ± 11 | 67 ± 10 | 0.393 |
| Blood pressure | ||||||||||||
| Systolic—mmHg | 136 ± 18 | 135 ± 16 | 0.934 | 134 ± 16 | 128 ± 16 | 0.279 | 133 ± 19 | 125 ± 16 | 0.115 | 132 ± 20 | 128 ± 15 | 0.318 |
| Diastolic—mmHg | 81 ± 14 | 82 ± 13 | 0.964 | 80 ± 13 | 80 ± 11 | 0.876 | 80 ± 12 | 80 ± 9 | 0.925 | 82 ± 11 | 79 ± 11 | 0.197 |
| Echocardiography | ||||||||||||
| LV-EF—% | 48 ± 6.8 | 51 ± 5.0 | 0.183 | 48 ± 6.2 | 51 ± 4.6 | 0.852 | 48 ± 6.1 | 51 ± 4.7 | 0.333 | 48 ± 6.4 | 51 ± 4.4 | 0.375 |
| LVEDD—mm | 50 ± 5 | 49 ± 5 | 0.365 | 50 ± 6 | 49 ± 5 | 0.864 | 49 ± 5 | 48 ± 5 | 0.449 | 50 ± 6 | 48 ± 6 | 0.994 |
| LVESD—mm | 36 ± 8 | 34 ± 6 | 0.386 | 36 ± 9 | 35 ± 5 | 0.595 | 35 ± 8 | 34 ± 5 | 0.187 | 37 ± 8 | 33 ± 6 | 0.284 |
| IVSd—mm | 10 ± 2 | 10 ± 1 | 0.94 | 10 ± 2 | 11 ± 2 | 0.764 | 10 ± 2 | 11 ± 2 | 0.63 | 10 ± 2 | 10 ± 1 | 0.497 |
| LV mass index—g/m2 | 91 ± 21 | 86 ± 19 | 0.474 | 94 ± 24 | 87 ± 19 | 0.448 | 90 ± 21 | 84 ± 19 | 0.701 | 89 ± 23 | 84 ± 17 | 0.807 |
| LA area—cm2 | 20 ± 4.2 | 20 ± 3.7 | 0.484 | 20 ± 5.3 | 18 ± 4.3 | 0.082 | 20 ± 5.7 | 19 ± 4.8 | 0.691 | 20 ± 4.1 | 18 ± 4.0 | 0.503 |
| LA volume index—mL/m2 | 31 ± 11 | 28 ± 9 | 0.414 | 30 ± 13 | 26 ± 10 | 0.3 | 30 ± 13 | 28 ± 10 | 0.84 | 31 ± 12 | 26 ± 9 | 0.239 |
| E—m/s | 0.78 ± 0.14 | 0.80 ± 0.20 | 0.686 | 0.80 ± 0.12 | 0.73 ± 0.20 | 0.003 | 0.78 ± 0.11 | 0.72 ± 0.18 | 0.005 | 0.78 ± 0.13 | 0.72 ± 0.21 | 0.001 |
| A—m/s | 0.73 ± 0.17 | 0.82 ± 0.17 | 0.095 | 0.74 ± 0.20 | 0.81 ± 0.15 | 0.786 | 0.75 ± 0.19 | 0.80 ± 0.15 | 0.55 | 0.73 ± 0.20 | 0.83 ± 0.15 | 0.927 |
| E/A | 1.18 ± 0.53 | 0.97 ± 0.22 | 0.121 | 1.20 ± 0.55 | 0.88 ± 0.20 | 0.042 | 1.16 ± 0.58 | 0.89 ± 0.23 | 0.181 | 1.21 ± 0.52 | 0.85 ± 0.23 | 0.038 |
| eʹ septal—cm/s | 7.2 ± 1.7 | 7.5 ± 1.9 | 0.603 | 6.6 ± 2.0 | 7.8 ± 2.1 | 0.077 | 7.2 ± 1.6 | 7.5 ± 2.0 | 0.785 | 7.2 ± 1.6 | 7.8 ± 2.1 | 0.47 |
| eʹ lateral—cm/s | 9.8 ± 2.0 | 10.4 ± 1.8 | 0.319 | 9.6 ± 2.4 | 10.1 ± 2.4 | 0.97 | 9.5 ± 1.9 | 9.8 ± 2.3 | 0.84 | 9.3 ± 2.0 | 10.4 ± 2.9 | 0.262 |
| eʹ mean | 8.5 ± 1.5 | 8.9 ± 1.6 | 0.361 | 8.1 ± 1.8 | 8.9 ± 2.1 | 0.352 | 8.4 ± 1.3 | 8.7 ± 2.0 | 0.968 | 8.3 ± 1.5 | 9.1 ± 2.3 | 0.28 |
| E/eʹ mean | 9.3 ± 2.2 | 9.2 ± 2.6 | 0.898 | 10.1 ± 1.4 | 8.5 ± 2.2 | 0.005 | 9.5 ± 1.5 | 8.5 ± 2.4 | 0.079 | 9.7 ± 1.9 | 8.3 ± 2.9 | 0.004 |
| DT—msec | 198 ± 54 | 206 ± 45 | 0.61 | 189 ± 45 | 212 ± 35 | 0.234 | 202 ± 54 | 215 ± 43 | 0.624 | 196 ± 59 | 218 ± 59 | 0.261 |
| RVSP—mmHg + CVP | 28 ± 6 | 29 ± 4 | 0.515 | 26 ± 5 | 26 ± 6 | 0.827 | 25 ± 4 | 29 ± 10 | 0.261 | 27 ± 8 | 26 ± 11 | 0.632 |
| GLS (endocardial layer) | − 17 ± 5.3 | − 19 ± 4.1 | 0.107 | − 17 ± 4.8 | − 19 ± 3.4 | 0.877 | − 17 ± 4.4 | − 19 ± 3.7 | 0.735 | − 17 ± 4.6 | − 19 ± 2.7 | 0.608 |
Effect of empagliflozin on metabolic parameters and renal function
Consistent with the initiation of renal tubule-glomerular feedback, empagliflozin significantly decreased eGFR from 77 ± 21 mL/min/1.73 m2 at baseline to 70 ± 19 mL/min/1.73 m2 (p = 0.014) after 1 day of treatment (Fig. 2c and Table 2) and increased serum cystatin C compared to placebo (Fig. 2d and Table 2). 24 h urinary sodium excretion increased in empagliflozin-treated patients without reaching statistical significance (Table 2). In addition, empagliflozin increased electrolyte-free water clearance from 166 ± 830 mL/24 h at baseline to 417 ± 802 mL/24 h after 1 day (p = 0.011), an effect that was sustained over the 3 month study period (Table 2).
Metabolic parameters and renal function. Urinary glucose excretion (), 24 h urinary volume (), eGFR (), and plasma cystatin C levels () in patients with type 2 diabetes treated with empagliflozin (n = 20; black line) or placebo (n = 22; blue dotted line). Data are shown as mean ± standard error at baseline, after 1 day, 3 days, and 3 months. p-values are calculated from Wald tests for the intervention effect at each visit a b c d
Effect of empagliflozin on echocardiographic parameters
Changes in E/eʹ did not correlate with changes in urinary volume, urinary glucose or sodium excretion, left ventricular mass index or electrolyte-free water clearance (Additional file: Figure S1). 1
Left ventricular diastolic function. Early mitral inflow velocity relative to early diastolic left ventricular relaxation (E/eʹ) in patients with type 2 diabetes treated with empagliflozin (n = 20; black line) or placebo (n = 22; blue dotted line). Data are shown as mean ± standard error at baseline, after 1 day, 3 days, and 3 months. p-values are calculated from Wald tests for the intervention effect at each visit
Safety
| Placebo (N = 22) | Empagliflozin (N = 20) | |
|---|---|---|
| Adverse events | 10 | 5 |
| Serious adverse events | 4 | 6 |
| Hypoglycemic events | 2 | 4 |
| Death | 0 | 0 |
| Adverse event leading to discontinuation of a study drug | 0 | 1 |
| Acute renale failure | 0 | 0 |
| Event consistent with volume depletion | 0 | 3 |
| Thromboembolic event | 0 | 1 |
| Diabetic ketoacidosis | 0 | 0 |
| Urinary tract infection | 0 | 1 |
| Genital infection | 0 | 4 |
| Bone fracture | 0 | 0 |
Discussion
In this randomized, placebo-controlled, double-blind study in patients with T2D and prevalent ASCVD or high CV risk, resembling the populations studied in CVOTs with SGLT2 inhibitors, empagliflozin had no significant effect on hemodynamic parameters including systemic vascular resistance index, cardiac index, stroke volume indexor pulse rate after 1 or 3 days of treatment nor after 3 months. These data suggest that the early reduction in HF hospitalization seen in EMPA-REG OUTCOME [1], the CANVAS program [2], CREDENCE [16],DECLARE [4] and VERTIS [5] is unlikely to be caused by changes in these parameters. However, we found a rapid improvement in left ventricular filling pressure as shown by a reduction of early mitral inflow velocity relative to early diastolic left ventricular relaxation (E/eʹ) as a main measure of diastolic function, an effect already significant after one day of treatment and sustained until the end of the study. This was attributable to reduced early diastolic transmitral inflow (E), most likely a consequence of persistently increased diuresis induced by empagliflozin being apparent throughout the whole study period, whereas no difference was observed for early diastolic left ventricular relaxation.
The lack of a hemodynamic response to SGLT2 inhibition seen here differs from the response to classic diuretic drugs like loop diuretics. Acutely, loop diuretics increase urine excretion by reducing intravasal volume with apparent hemoconcentration and the diuretic-induced preload reduction impairs cardiac output with a compensatory increase in pulse rate and systemic vascular resistance [17]. In contrast, SGLT2 inhibition in our study rapidly expanded urinary volume excretion already after one day—along with an increase in electrolyte-free water clearance—which did not effect cardiac index, systemic vascular resistance nor pulse rate. Furthermore, treatment with empagliflozin did not decrease serum sodium levels as a common side effect of loop diuretics—with hyponatraemia being a powerful predictor of mortality in patients with heart failure [18]. So, it has been suggested that SGLT2 inhibition more efficiently reduces interstitial relative to intravasal volume in comparison to loop diuretics [19], which maybe supported by increased electrolyte free water clearance upon empagliflozin treatment in our study. Early effects of empagliflozin on body fluid content was further suggested by significant reduction of body weight at day 1 and 3 of treatment, which was however not sustained at the 3 month time point despite ongoing diuretic efficacy. Consistently Schork et al. reported rapid loss of extracellular water by SGLT2 inhibition using bioimpedance spectroscopy [20], which was not anymore apparent after 3 months of treatment. This suggests adaptive mechanisms of fluid regulation to compensate for the ongoing loss of urinary volume at later time points. Furthermore this might indicate additional mechanisms to be of relevance for the sustained reduction of heart failure events in respective CVOTs [1–5]. Importantly, SGLT2 inhibition has recently been found to reduce heart failure events to a similar extend in patients with and without diabetes demonstrating broad therapeutic efficacy of the drug class in HFrEF [7, 8].
The main—albeit exploratory—finding of our study, the early and sustained improvement of left ventricular filling pressure as indicated by E/eʹ in empagliflozin treated patients might provide important information to better understand the early beneficial effects on HF hospitalization seen in SGLT2 inhibitor outcome trials. Patient with T2D are at risk for diastolic dysfunction, resulting from increased left ventricular fibrosis, stiffness, and wall thickness as predisposing factors for heart failure with preserved ejection fraction. Consequential increase of left ventricular filling pressure causes augmentation of E/eʹ (early transmitral inflow velocity / early diastolic mitral annular tissue velocity) as an established echocardiographic parameter of diastolic dysfunction.
Given that impaired diastolic function is a crucial pathophysiological feature of HF, mainly subclinical HFpEF,—often present long before HF becomes clinical apparent—our data bolster the hypothesis that SGLT2 inhibitors could prevent the development of HF by improving left ventricular filling pressure in patients with T2D. An observatory study of 37 patients with T2D demonstrated a reduction in E/eʹ, which was also attributable to reduced early transmitral inflow velocity (E) and combined with a decrease in systolic blood pressure and LVMI after 3 months of treatment with canagliflozin [21]. In contrast, Soga et al. observed a decrease in E/eʹ unrelated to changes of blood pressure in 58 T2D patients with HF treated for 6 months with dapagliflozin under non-randomised conditions. In this study the improvement in diastolic function was independent of E, but attributable to reduced early diastolic left ventricular relaxation and paralleled by a reduction in LVMI [22]. Furthermore Higashikawa et al. reported Tofogliflozin to improve E/eʹ in 42 elderly patients with diabetes [23].
Our randomized, placebo-controlled study extends the understanding of SGLT2 inhibitors’ effect on diastolic function by demonstrating time dependent effects of empagliflozin on left ventricular filling pressure being apparent already after 1 day of treatment. This might be attributable to empagliflozin dependent osmotic diuresis with electrolyte free water excretion leading to cardiac preload reduction as suggested by reduced early mitral inflow velocity E. Still, modulation of E/eʹ did not correlate with changes in urinary volume, urinary glucose or sodium excretion, left ventricular mass index, electrolyte-free water clearance. Additional studies using larger populations will be required to clarify the relevance of volume unloading by SGLT2 inhibition for diastolic function. While observational studies suggest SGLT2 inhibition to improve outcome in patients with HFpEF, this is currently evaluated in large clinical trials (ClinicalTrials.gov Identifier: NCT03619213↗) [24, 25].
This study has certain limitations. First, hemodynamic parameters were assessed by non-invasive pulse contour analysis (ClearSight System®). However, this technique has extensively been validated against invasive hemodynamic measurements and is an established method in clinical practice [14, 26, 27]. Second, we did not measure other hemodynamic parameters such as pulse pressure, central arterial blood pressure, markers of arterial stiffness that have been shown to be affected by empagliflozin treatment for 6 weeks [28]. Third, the immediate improvement in diastolic function, shown by an early reduction of E/eʹ upon empagliflozin treatment, is an exploratory finding in a limited number of patients, and warrants confirmation in a larger study with changes in diastolic function defined as primary outcomes. Still, the present study was randomized, blinded and placebo-controlled, and changes in cardiac function assessed by echocardiography were predefined exploratory endpoints. Finally, improved diastolic function by empagliflozin treatment was not associated with reduced left ventricular mass index or reduced left atrial volume index nor RVSP after 3 months in our study, while others have found SGLT2 inhibition to reduce left ventricular mass [29]. Additional studies using larger populations will be required to investigate effect of SGLT2 inhibition on structural changes of the left ventricle.
Conclusion
Taken together, our data suggest that empagliflozin treatment of patients with T2D and ASCVD/high CV risk leads to an immediate volume unloading and a rapid and sustained improvement of left ventricular filling pressure. These mechanisms could contribute to the early beneficial effects of SGLT2 inhibitors on HF hospitalisation seen in various SGLT2 inhibitor CVOTs.
Supplementary information
Additional file 1: Figure S1. Change of E/e’ for each single patient treated with empagliflozin (n=20; black line) or placebo (n=22; blue dotted line) after 1 day, 3 days, and 3 months.